MedPath

CENTOCOR, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
1.2K
Market Cap
-
Website
http://www.centocor.com

Clinical Trials

76

Active:0
Completed:70

Trial Phases

4 Phases

Early Phase 1:1
Phase 1:18
Phase 2:19
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (74 trials with phase data)• Click on a phase to view related trials

Phase 3
36 (48.6%)
Phase 2
19 (25.7%)
Phase 1
18 (24.3%)
Early Phase 1
1 (1.4%)

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: CNTO 328 (Sp2/0-derived)
Drug: CNTO 328 (CHO-derived)
Drug: Placebo
First Posted Date
2014-02-28
Last Posted Date
2015-02-05
Lead Sponsor
Centocor, Inc.
Target Recruit Count
145
Registration Number
NCT02074800

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2011-05-30
Last Posted Date
2017-10-02
Lead Sponsor
Centocor, Inc.
Target Recruit Count
49
Registration Number
NCT01362153

A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects

Phase 1
Completed
Conditions
Healthy Adult Chinese Males
Interventions
First Posted Date
2011-02-02
Last Posted Date
2014-05-28
Lead Sponsor
Centocor, Inc.
Target Recruit Count
24
Registration Number
NCT01288157

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 3
Withdrawn
Conditions
Multiple Myeloma
Interventions
Biological: Siltuximab, Velcade and dexamethasone
First Posted Date
2010-12-24
Last Posted Date
2013-01-28
Lead Sponsor
Centocor, Inc.
Registration Number
NCT01266811

A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: 200 mg golimumab or placebo
Drug: 400 mg golimumab or placebo
First Posted Date
2010-12-13
Last Posted Date
2013-09-04
Lead Sponsor
Centocor, Inc.
Target Recruit Count
49
Registration Number
NCT01258777
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 15
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.